Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

Akhtar, Othman S.; Modi, Karnav; Kim, Jongphil; Skelson, Lawrence; Smith, Eric; Al-Jumayli, Mohammed A.; Extermann, Martine; De Avila, Gabriel; Parker, Nathan; Castaneda Puglianini, Omar; Grajales Cruz, Ariel; Baz, Rachid; Blue, Brandon; Shain, Kenneth; Alsina, Melissa; Liu, Hien; Nishihori, Taiga; Jain, Michael D.; Locke, Frederick L.; Hansen, Doris K.; Freeman, Ciara L.

doi:10.1016/j.jtct.2023.12.010

Transplantation and Cellular Therapy

2024

DOI: 10.1016/j.jtct.2023.12.010

|View full text |Cite

Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

Othman S. Akhtar,

Karnav Modi,

Jongphil Kim

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

Cordas dos Santos,

Tix,

Shouval

et al. 2024

Nat Med

View full text Add to dashboard Cite

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

Cordas dos Santos,

Tix,

Shouval

et al. 2024

Nat Med

View full text Add to dashboard Cite

Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies

Akhtar,

Szabo,

Bhatlapenumarthi

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryThe Glasgow prognostic score (GPS) and CAR‐HEMATOTOX (CAR‐HT) score identify multiple myeloma (MM) patients at high risk for immune‐mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T‐cell redirecting bispecific antibodies (bsAb) is unclear. This multi‐centre retrospective study examines the association of baseline GPS and CAR‐HT scores with outcomes in 126 MM patients treated with bsAb. Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high‐risk CAR‐HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies.

show abstract

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Zanwar,

Sidana,

Shune

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain incompletely characterized. We included patients with RRMM treated with ide-cel between May 2021 and April 2023 across 11 US academic institutions. Visceral or soft tissue lesions non-contiguous from bone was classified as EMD. Time-to-event analyses were performed from date of ide-cel infusion. Among 351 patients, 84 (24%) had EMD prior to infusion. The median follow-up from ide-cel infusion was 18.2 months (95% CI: 17-19.3). The day 90 overall response rates (ORR) were 52% vs. 82% for the EMD and non-EMD cohorts, respectively (p < 0.001). The median progression-free survival (PFS) was 5.3 months (95% CI: 4.1–6.9) for the EMD cohort vs. 11.1 months (95% CI: 9.2–12.6; p < 0.0001) for the non-EMD cohort. In a multivariable analysis, EMD was an independent predictor of inferior PFS [hazard ratio 1.5 (1.1–2.2), p = 0.02]. The median overall survival was 14.8 months [95% CI: 9-Not reached (NR)] vs. 26.9 months (26.3 vs. NR, p = 0.006) for the EMD and non-EMD cohorts, respectively. Extramedullary disease represents an independent predictor of inferior day 90 ORR and PFS among patients treated with ide-cel.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

Cited by 3 publications

References 29 publications

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Contact Info

Product

Resources

About